Ab­b­Vie show­cas­es pos­i­tive PhI­II da­ta for Rin­voq; RAPT prices on low end for IPO

→ Ab­b­Vie is tout­ing pos­i­tive da­ta from its SE­LECT-PsA 2 Phase III study of Rin­voq for the treat­ment of pso­ri­at­ic arthri­tis. The study showed that both dos­es of the drug (upadac­i­tinib; 15 mg and 30 mg, once dai­ly) met the pri­ma­ry end­point of ACR20 re­sponse at week 12 ver­sus place­bo in adult pa­tients with ac­tive pso­ri­at­ic arthri­tis who have re­spond­ed in­ad­e­quate­ly to one or more bi­o­log­ic dis­ease-mod­i­fy­ing an­ti-rheumat­ic drugs. The re­sults come af­ter the EMA backed the oral JAK1 in­hibitor ear­li­er this month, de­spite the FDA slap­ping a dread­ed black box warn­ing with its ap­proval rough­ly two months pri­or.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER